- Home
- FLC vs ENTA Comparison
FLC vs ENTA Comparison
Compare FLC & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLC
- ENTA
- Stock Information
- Founded
- FLC 2003
- ENTA 1995
- Country
- FLC United States
- ENTA United States
- Employees
- FLC N/A
- ENTA N/A
- Industry
- FLC Trusts Except Educational Religious and Charitable
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- FLC Finance
- ENTA Health Care
- Exchange
- FLC Nasdaq
- ENTA Nasdaq
- Market Cap
- FLC 174.2M
- ENTA 160.3M
- IPO Year
- FLC N/A
- ENTA 2013
- Fundamental
- Price
- FLC $16.31
- ENTA $7.89
- Analyst Decision
- FLC
- ENTA Buy
- Analyst Count
- FLC 0
- ENTA 4
- Target Price
- FLC N/A
- ENTA $18.00
- AVG Volume (30 Days)
- FLC 37.8K
- ENTA 181.3K
- Earning Date
- FLC 01-01-0001
- ENTA 08-04-2025
- Dividend Yield
- FLC 6.64%
- ENTA N/A
- EPS Growth
- FLC N/A
- ENTA N/A
- EPS
- FLC N/A
- ENTA N/A
- Revenue
- FLC N/A
- ENTA $64,462,999.00
- Revenue This Year
- FLC N/A
- ENTA N/A
- Revenue Next Year
- FLC N/A
- ENTA $0.48
- P/E Ratio
- FLC N/A
- ENTA N/A
- Revenue Growth
- FLC N/A
- ENTA N/A
- 52 Week Low
- FLC $12.62
- ENTA $4.09
- 52 Week High
- FLC $15.45
- ENTA $17.24
- Technical
- Relative Strength Index (RSI)
- FLC 65.10
- ENTA 67.33
- Support Level
- FLC $16.86
- ENTA $6.95
- Resistance Level
- FLC $17.09
- ENTA $8.23
- Average True Range (ATR)
- FLC 0.12
- ENTA 0.40
- MACD
- FLC 0.01
- ENTA 0.00
- Stochastic Oscillator
- FLC 84.21
- ENTA 75.11
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.